4CPS-077 Genetic variants affecting bisoprolol response in cardiovascular diseases

Background and importanceβ-Blockers are commonly prescribed to treat multiple cardiovascular (CV) diseases, but, frequently, adverse drug reactions and intolerance limit their use in clinical practice. Interindividual variability in response to β-blockers may be explained by genetic differences. In fact, pharmacogenetic interactions for some of these drugs have been widely studied, such as metoprolol. But studies that explore genetic variants affecting bisoprolol response are inconclusive, limited or confusing because of mixed results with other β-blockers, different genetic polymorphisms observed, endpoint studied, and so on.Aim and objectivesThe aim of this study was to perform a systematic review in order to find relevant genetic variants affecting bisoprolol response and to perform a meta-analysis.Material and methodsSystematic review of genetic variants affecting bisoprolol. We performed a search in Pubmed on 15 January 2021 using MESH terms in the following argument: (‘Bisoprolol’ OR ‘Metoprolol’ OR ‘Adrenergic Beta antagonist’) AND (‘Pharmacogenetic’ OR ‘Single Nucleotide Polymorphism (SNP)’ OR Polymorphism’). We included ‘metoprolol’ and ‘adrenergic beta antagonist’ to detect research with combined results of various β-blockers.We conducted a random-effects meta-analysis in recessive, dominant, codominant and overdominant models for the G risk allele in order to assess the association between ADRB1 A389G (rs1801253) and bisoprolol.We used R statistics software, version 3.6.2, package ‘meta’ to conduct the meta-analysis (https://CRAN.R-project.org/package=meta) and Harbord′s test in order to quantitatively assess publication bias, considering a p value